|
|
| | L-Leucine, L-arginyl-L-alanyl-L-lysyl-L-phenylalanyl-L-lysyl-L-glutaminyl-L-leucyl- Basic information |
| | L-Leucine, L-arginyl-L-alanyl-L-lysyl-L-phenylalanyl-L-lysyl-L-glutaminyl-L-leucyl- Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | pka | 3.41±0.10(Predicted) | | Sequence | RAKFKQLL |
| | L-Leucine, L-arginyl-L-alanyl-L-lysyl-L-phenylalanyl-L-lysyl-L-glutaminyl-L-leucyl- Usage And Synthesis |
| Uses | EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases[1]. | | References | [1] Misko I S, et al. Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease[J]. Proceedings of the National Academy of Sciences, 1999, 96(5): 2279-2284. DOI:10.1073/pnas.96.5.2279 |
| | L-Leucine, L-arginyl-L-alanyl-L-lysyl-L-phenylalanyl-L-lysyl-L-glutaminyl-L-leucyl- Preparation Products And Raw materials |
|